Skip to main content
. 2023 May 30;15(11):2993. doi: 10.3390/cancers15112993

Table 2.

Prior and ongoing treatments at the time of the first dose of the SARS-CoV-2 vaccine.

N = 200 (%)
The median number of prior treatments (range) 1 (0–8)
Treatment naïve patients 33 (16.5)
Previously treated patients 167 (83.5)
Front-line chemoimmunotherapy only 20 (10.3)
Targeted agents 147 (73.5)
Ibrutinib-based treatment (1) 72 (36)
Front-line 42 (21.0)

  • Ibrutinib single agent

 28 (14)

  • ibrutinib + rituximab

 14 (7)
Advanced-line Ibrutinib (1) 30 (15.0)
Venetoclax-based treatment 75 (37.5)
Front-line venetoclax + rituximab (2) 27 (13.5)
Advanced-line venetoclax ± rituximab 48 (24.0)

  • Venetoclax + rituximab (3)

 21 (10.5)

  • Venetoclax single agent

 27 (13.5)
Median number of months (range) between vaccine and start of:

  • Chemoimmunotherapy

 54.5 (9–210)

  • Ibrutinib or venetoclax–based treatment

 18 (3–90.5)

  • Ibrutinib-based treatment

 36 (2–90.3)

  • Venetoclax-based treatment

 13 (0.5–44)
Patients previously treated with rituximab 135 (77.5)

  • Last rituximab within 12 months before vaccination

 33 (16.5)

  • Last rituximab more than 12 months before vaccination

 102 (51–0)

(1) Ongoing ibrutinib-based treatment: 72/72 patients. (2) Ongoing treatment with front-line venetoclax + rituximab: 17/27 patients, median time from venetoclax + rituximab discontinuation: 12.5 months (range, 5–17 months). (3) Ongoing treatment with advanced-line venetoclax+ rituximab, 21/21 patients.